Biotech's Worst Winner of 2012  
1/4/2013 9:04:10 AM

Shares of Isis Pharmaceuticals rose 40% in 2012 as an advisory panel to the Food and Drug Administration voted that its experimental drug for a rare, genetic form of high cholesterol should be approved. That sounds pretty good, right? Sure — so long as you don’t stop to consider what might have been for Isis or the drug, mipomersen, if it had lived up to its early promise.